Meta-analysis of these two studies revealed that patients with the increased plasma level of CRABP2 were not associated with poor PFS with combined HR: 1.15% CI: 0.63–2.09, Fig. 3) in lung cancer. This evidence concerns the gene CRABP2 and lung cancer.